McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Corporation

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on McKesson (MCK), uniQure (QURE) and Establishment Lab...

Analysts Offer Insights on Healthcare Companies: McKesson (MCK), uniQure (QURE) and Establishment Labs Holdings (ESTA)

McKesson ( ($MCK) ) has provided an update. McKesson Corporation reported that on August 25, 2026, it discovered a cybersecurity incident affecting...

McKesson Reports Recent Cybersecurity Incident Under Regulation FD

In a report released today, Stephen Baxter from Wells Fargo assigned a Hold rating to McKesson, with a price target of $933.00. Baxter covers the H...

Wells Fargo Releases a Hold Rating on McKesson (MCK)

Bank of America Securities analyst Allen Lutz reiterated a Buy rating on McKesson today and set a price target of $1,050.00. Lutz covers the Health...

Bank of America Securities Reaffirms Their Buy Rating on McKesson (MCK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on McKesson (MCK) and OnKure Therapeutics (OKUR) with b...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MCK	$922.20	-0.28%	146.81K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MCK	$922.20	-0.3%	146.81K
3
4
5
6

MCK

Get McKesson Corporation Data in Excel

Get McKesson Corporation Data in Excel